AIA Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-28
Closed -$13.4K 336
2023
Q1
$13.4K Sell
28
-69
-71% -$32.3K ﹤0.01% 394
2022
Q4
$40.8K Buy
97
+65
+203% +$26.2K ﹤0.01% 389
2022
Q3
$13K Sell
32
-57
-64% -$28.4K ﹤0.01% 409
2022
Q2
$44K Hold
89
﹤0.01% 447
2022
Q1
$50K Hold
89
﹤0.01% 518
2021
Q4
$67K Buy
+89
New +$66.6K ﹤0.01% 455

Other funds holding BIO

AIA Group's BIO Position: Q2 2023 in Review

AIA Group sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 28 shares — an estimated $13.4K sold.

AIA Group first reported a position in BIO in Q4 2021 and held it in 6 quarters. The position peaked at $67K in Q4 2021. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • AIA Group reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • AIA Group sold 28 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $13.4K.
  • AIA Group first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 6 quarters.
  • AIA Group's Bio-Rad Laboratories Class A position peaked at $67K in Q4 2021.
  • 469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on AIA Group's 13F filing for Q2 2023, filed 28 Jul 2023.